Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma

Previous anti-EGFR trials in unselected gastroesophageal adenocarcinoma (GEA) patients were resoundingly negative. We identified EGFR amplification in 5% (19/363) of patients at the University of Chicago, including 6% (8/140) who were prospectively screened with intention-to-treat using anti-EGFR th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Discov
Asıl Yazarlar: Maron, Steven B., Alpert, Lindsay, Kwak, Heewon A., Lomnicki, Samantha, Chase, Leah, Xu, David, O’Day, Emily, Nagy, Rebecca J., Lanman, Richard B., Cecchi, Fabiola, Hembrough, Todd, Schrock, Alexa, Hart, John, Xiao, Shu-Yuan, Setia, Namrata, Catenacci, Daniel V.T.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5984701/
https://ncbi.nlm.nih.gov/pubmed/29449271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-1260
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller